Pregnancy outcomes according to intervention groups. by Richard S. Legro (8086748)

Fig 1 - by Madison Luick (17539007)

Baseline characteristics of the patients. by Richard S. Legro (8086748)

Effect of 16-week lifestyle intervention programs on biometric and biochemical parameters. by Richard S. Legro (8086748)

Summary of overall cost per patient for HIV testing services, ART initiation and ART maintenance. by Rachel Mukora (10949459)

Kaplan–Meier curves for pregnancy loss among those who conceived. by Richard S. Legro (8086748)

Survival of <i>C</i>. <i>jejuni</i> farm isolates in broth cultures under aerobic shaking at 41.5°C. by Anniina Jaakkonen (5573006)

“…<p>Mean colony counts of five experiments are shown at time points 0 h (maximum standard error of the mean ±0.2), 6 h (±0.3), 12 h (±0.5), and 24 h (±1.2) and mean colony counts of three experiments at 48 h (±2.1), and 72 h (±1.4). …”

Serious adverse events (all) and adverse events (with more than 2% of patients experiencing them) between the intervention groups. by Richard S. Legro (8086748)

Good live birth, live birth, and conception per study phase and treatment cycles. by Richard S. Legro (8086748)

Early IFNγ/TNF responses in Vδ2⁺ γδT-cells to brief PMA/Ionomycin stimulation improve with the resolution of AHB but not CHB Flare. by Kyong-Mi Chang (267170)

“…</b> Graphs compare serum ALT (log IU/L), HBV DNA (log IU/L), %Vδ2⁺ γδT-cells/CD3⁺ T-cells, %Tbet/Vδ2⁺ γδT-cells, %IFNγ⁺/Vδ2⁺ γδT-cells, %IFNγ^-TNF^-/Vδ2⁺ γδT-cells for 7 CHB-Flare subjects <b>(A)</b> and 7 AHB subjects <b>(B)</b> at the earliest time point (T1) within 1 weeks from initial clinical presentation for CHB flare or AHB and a later time point T2 with resolution of ALT flare or AHB. …”

Table_1_Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.DOCX by Prajwal Boddu (5780843)

“…Three and one complete responses were observed at dose-levels “0” and “1,” respectively; the overall response rate (ORR) was 36% (4 of 11 patients). A ≥ 50% decrease in CXCR4 mean fluorescence intensity was observed in 4 of 9 patients by flow cytometry, indicating incomplete suppression of CXCR4-receptor occupancy.…”

Table_1_Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.DOCX by Prajwal Boddu (5780843)

“…Three and one complete responses were observed at dose-levels “0” and “1,” respectively; the overall response rate (ORR) was 36% (4 of 11 patients). A ≥ 50% decrease in CXCR4 mean fluorescence intensity was observed in 4 of 9 patients by flow cytometry, indicating incomplete suppression of CXCR4-receptor occupancy.…”

Image_1_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.jpeg by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Table_1_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.docx by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Image_6_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.jpeg by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Image_4_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.jpeg by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Image_2_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.jpeg by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Image_3_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.jpeg by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Image_7_Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.jpeg by Susan A. Kennedy (9456011)

“…A significant increase in eotaxin-3 (MD: 2.59 (95% CI: 0.23 to 4.96)), IL-15 (MD: 0.27 (95% CI: 0 to 0.54)) and decrease in bFGF (MD: 1.62 (95% CI: -2.99 to 0.26)) expression was observed between control and intervention cohorts at T2 (p<0.05).…”

Summary statistics for the individual fires. by Erin Conlisk (163376)

“…Consistent with other studies, topographic position, slope, elevation, and vegetation were also significantly associated with the likelihood of a structure being damaged during the wildfire. …”